DE69723688D1 - Verbindungen mit zytoprotektiver wirkung - Google Patents

Verbindungen mit zytoprotektiver wirkung

Info

Publication number
DE69723688D1
DE69723688D1 DE69723688T DE69723688T DE69723688D1 DE 69723688 D1 DE69723688 D1 DE 69723688D1 DE 69723688 T DE69723688 T DE 69723688T DE 69723688 T DE69723688 T DE 69723688T DE 69723688 D1 DE69723688 D1 DE 69723688D1
Authority
DE
Germany
Prior art keywords
methods
provides compositions
connections
oxidation
cytoprotective effect
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE69723688T
Other languages
English (en)
Other versions
DE69723688T2 (de
Inventor
C Franson
M Ottenbrite
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Virginia Commonwealth University
Original Assignee
Virginia Commonwealth University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Virginia Commonwealth University filed Critical Virginia Commonwealth University
Publication of DE69723688D1 publication Critical patent/DE69723688D1/de
Application granted granted Critical
Publication of DE69723688T2 publication Critical patent/DE69723688T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C309/00—Sulfonic acids; Halides, esters, or anhydrides thereof
    • C07C309/01—Sulfonic acids
    • C07C309/02—Sulfonic acids having sulfo groups bound to acyclic carbon atoms
    • C07C309/03—Sulfonic acids having sulfo groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton
    • C07C309/13—Sulfonic acids having sulfo groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton containing nitrogen atoms, not being part of nitro or nitroso groups, bound to the carbon skeleton
    • C07C309/14—Sulfonic acids having sulfo groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton containing nitrogen atoms, not being part of nitro or nitroso groups, bound to the carbon skeleton containing amino groups bound to the carbon skeleton
    • C07C309/15—Sulfonic acids having sulfo groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton containing nitrogen atoms, not being part of nitro or nitroso groups, bound to the carbon skeleton containing amino groups bound to the carbon skeleton the nitrogen atom of at least one of the amino groups being part of any of the groups, X being a hetero atom, Y being any atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C219/00—Compounds containing amino and esterified hydroxy groups bound to the same carbon skeleton
    • C07C219/02—Compounds containing amino and esterified hydroxy groups bound to the same carbon skeleton having esterified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C219/04—Compounds containing amino and esterified hydroxy groups bound to the same carbon skeleton having esterified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated
    • C07C219/08—Compounds containing amino and esterified hydroxy groups bound to the same carbon skeleton having esterified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having at least one of the hydroxy groups esterified by a carboxylic acid having the esterifying carboxyl group bound to an acyclic carbon atom of an acyclic unsaturated carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
    • C07C229/02—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C229/04—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated
    • C07C229/06—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one amino and one carboxyl group bound to the carbon skeleton
    • C07C229/10—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one amino and one carboxyl group bound to the carbon skeleton the nitrogen atom of the amino group being further bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings
    • C07C229/16—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one amino and one carboxyl group bound to the carbon skeleton the nitrogen atom of the amino group being further bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings to carbon atoms of hydrocarbon radicals substituted by amino or carboxyl groups, e.g. ethylenediamine-tetra-acetic acid, iminodiacetic acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C233/00—Carboxylic acid amides
    • C07C233/01—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C233/34—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by amino groups
    • C07C233/35—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by amino groups with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom
    • C07C233/38—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by amino groups with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom having the carbon atom of the carboxamide group bound to a carbon atom of an acyclic unsaturated carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C235/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
    • C07C235/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton
    • C07C235/28—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton the carbon skeleton being acyclic and unsaturated
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C309/00—Sulfonic acids; Halides, esters, or anhydrides thereof
    • C07C309/01—Sulfonic acids
    • C07C309/02—Sulfonic acids having sulfo groups bound to acyclic carbon atoms
    • C07C309/03—Sulfonic acids having sulfo groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton
    • C07C309/13—Sulfonic acids having sulfo groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton containing nitrogen atoms, not being part of nitro or nitroso groups, bound to the carbon skeleton
    • C07C309/14—Sulfonic acids having sulfo groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton containing nitrogen atoms, not being part of nitro or nitroso groups, bound to the carbon skeleton containing amino groups bound to the carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
    • C07C69/66—Esters of carboxylic acids having esterified carboxylic groups bound to acyclic carbon atoms and having any of the groups OH, O—metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety
    • C07C69/73—Esters of carboxylic acids having esterified carboxylic groups bound to acyclic carbon atoms and having any of the groups OH, O—metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety of unsaturated acids
    • C07C69/732—Esters of carboxylic acids having esterified carboxylic groups bound to acyclic carbon atoms and having any of the groups OH, O—metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety of unsaturated acids of unsaturated hydroxy carboxylic acids

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Dermatology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Immunology (AREA)
  • Toxicology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pulmonology (AREA)
  • Urology & Nephrology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
DE69723688T 1996-04-15 1997-04-15 Verbindungen mit zytoprotektiver wirkung Expired - Fee Related DE69723688T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US08/632,030 US5859271A (en) 1996-04-15 1996-04-15 Cytoprotective compounds
PCT/US1997/006283 WO1997038966A2 (en) 1996-04-15 1997-04-15 Cytoprotective compounds
US632030 2000-08-02

Publications (2)

Publication Number Publication Date
DE69723688D1 true DE69723688D1 (de) 2003-08-28
DE69723688T2 DE69723688T2 (de) 2004-04-15

Family

ID=24533782

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69723688T Expired - Fee Related DE69723688T2 (de) 1996-04-15 1997-04-15 Verbindungen mit zytoprotektiver wirkung

Country Status (9)

Country Link
US (4) US5859271A (de)
EP (1) EP0898559B1 (de)
JP (1) JP2000509372A (de)
AT (1) ATE245623T1 (de)
AU (1) AU2731097A (de)
DE (1) DE69723688T2 (de)
ES (1) ES2206708T3 (de)
IL (1) IL126542A0 (de)
WO (1) WO1997038966A2 (de)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5859271A (en) * 1996-04-15 1999-01-12 Virginia Commonwealth University Cytoprotective compounds
AR023819A1 (es) * 1999-05-03 2002-09-04 Astrazeneca Ab FORMULACIoN FARMACEUTICA, KIT DE PARTES Y UTILIZACION DE DICHA FORMULACION
US7749539B2 (en) * 2000-11-30 2010-07-06 Efrat Biopolymers Ltd. Polymeric formulations for drug delivery
US20030069639A1 (en) * 2001-04-14 2003-04-10 Tom Sander Methods and compositions for repair or replacement of joints and soft tissues
US20040242632A1 (en) * 2001-11-09 2004-12-02 Charous B. Lauren Method for treating inflammatory bowel disease
AUPS282602A0 (en) 2002-06-07 2002-06-27 Garvan Institute Of Medical Research Method of inhibiting cell proliferation
WO2003106625A2 (en) * 2002-06-13 2003-12-24 Amgen Inc. Hammerhead ribozymes
US20070243251A1 (en) * 2002-12-20 2007-10-18 Rajneesh Taneja Dosage Forms Containing A PPI, NSAID, and Buffer
US20040121004A1 (en) * 2002-12-20 2004-06-24 Rajneesh Taneja Dosage forms containing a PPI, NSAID, and buffer
US20110097410A1 (en) * 2007-08-24 2011-04-28 Berney Richard L Formulations of px compounds
WO2012119781A2 (en) * 2011-03-10 2012-09-13 University Of Geneva Novel lipids, phospholipids, phospholipid and lipid compositions and their use
US20130190270A1 (en) * 2012-01-24 2013-07-25 Hans W. J. Niessen Method for Improving Vein Performance in Bypass Surgery
EP3233964B1 (de) 2014-12-18 2020-06-17 Dexcel Pharma Technologies Ltd. Alternierende und semialternierende (poly)esteranhydrid-copolymere
KR101899345B1 (ko) 2017-02-10 2018-09-17 대봉엘에스 주식회사 TES Trioleate를 포함하는 자외선에 대한 피부 보호용 조성물
WO2018178963A1 (en) 2017-03-29 2018-10-04 Dexcel Pharma Technologies Ltd. Compositions comprising biodegradable copolymers
US20220409532A1 (en) * 2021-06-24 2022-12-29 Brian J. Huber Composition and method for a topical treatment for venom neutralization

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4701469A (en) * 1983-04-15 1987-10-20 Roussel Uclaf Triglycerides, process for therapeutical applications and compositions containing them
WO1988006445A1 (en) * 1987-02-24 1988-09-07 William Regelson Prostaglandin b1, macromolecules as anti-inflammatory agents
US5659049A (en) * 1988-02-18 1997-08-19 Virginia Commonwealth University Antioxidant, antiphospholipase derivatives of ricinoleic acid
US4927658A (en) * 1989-02-16 1990-05-22 Nabisco Brands, Inc. Tris-hydroxymethyl alkane esters as low calorie fat mimetics
EP0490919B1 (de) * 1989-08-29 2001-01-17 Virginia Commonwealth University Cytoprotektive substanzen mit ungesattigten kohlenwasserstoffresten von 16 bis 20 kohlenstoffatome
ES2062574T3 (es) * 1990-01-19 1994-12-16 Kao Corp Composicion suavizante liquida para tejidos.
GB2279948A (en) * 1993-05-07 1995-01-18 Unilever Plc Ricinoleic acid derivative
US5859271A (en) * 1996-04-15 1999-01-12 Virginia Commonwealth University Cytoprotective compounds

Also Published As

Publication number Publication date
IL126542A0 (en) 1999-08-17
WO1997038966A3 (en) 1998-02-26
US6020510A (en) 2000-02-01
JP2000509372A (ja) 2000-07-25
WO1997038966A2 (en) 1997-10-23
ES2206708T3 (es) 2004-05-16
US6600059B2 (en) 2003-07-29
US6423855B2 (en) 2002-07-23
EP0898559B1 (de) 2003-07-23
US20020002296A1 (en) 2002-01-03
EP0898559A2 (de) 1999-03-03
DE69723688T2 (de) 2004-04-15
AU2731097A (en) 1997-11-07
ATE245623T1 (de) 2003-08-15
US5859271A (en) 1999-01-12
US20030078417A1 (en) 2003-04-24

Similar Documents

Publication Publication Date Title
DE69723688D1 (de) Verbindungen mit zytoprotektiver wirkung
DE69419141D1 (de) Inhibitoren gegen thrombose
TR200002940T2 (tr) Parazitlerin sebep olduğu hastalıkların papain süperfamilyasından sistein proteazların inhibisyonu yoluyla tedavisi
CY1125022T1 (el) Μεθοδοι για θεραπεια καταστασεων που συνδυαζονται με εξαρτωμενη απο masp-2 ενεργοποιηση συμπληρωματος
MXPA05012880A (es) Inhibidores de complemento.
DE50103410D1 (de) Gleitschutz fur einen gehäusekopf medizinischer instrumente
NO942064L (no) yminhibitorer
EP0824918A4 (de) HEILUNG UND VORBEUGUNG VON DURCH NF-kappaB VERURSACHTEN ERKRANKUNGEN
PT1117296E (pt) Combinacao de bisfosfonato e de tetraciclina
ATE413386T1 (de) Ppar-gamma modulatoren
DK0840732T3 (da) Substituerede benzolactamforbindelser som substans P-antagonister
DE69709727D1 (de) Parazinon thrombin inhibitoren
TR200102029T2 (tr) 1-Heterosiklil ikameli diarilaminler.
TR199701074T1 (xx) Sinerjistik bile�imler.
ES2151741T3 (es) Benzamidinas dipeptidicas como inhibidores de quinino-genasas.
DE69936059D1 (de) Methoden zur prophylaxe und behandlung von schäden der wahrnehmungshärchenzellen und der cochlearen neuronen
TR199800773T2 (xx) Trombin inhibit�rleri.
NO20004052D0 (no) Glukokortikoidselektive antiinflammatoriske midler
ATE296283T1 (de) Zelladhäsion- und entzündungshemmende immunosuppressive verbindungen
ATE253351T1 (de) Desodoriende zubereitungen enthaltend wasserlösliche -(1,3)-glucane
DE69918933D1 (de) Hemmung von durch sulfat-reduzierende bakterien vermitteltem abbau durch verwendung von bakterien, die antimirkobrobielle stoffe ausscheiden
TR199801242T2 (xx) Bir antifungal ve bir k�k�rt bile�i�i i�eren bile�imler.
ID29195A (id) Metoda dan komposisi untuk menghambat polimerisasi hidrokarbon tidak jenuh secara etilenik
DE69829963D1 (de) Zusammensetzungen und verfahren zur behinderung der entladung von nematokyste
DE60329326D1 (de) Tace inhibitoren

Legal Events

Date Code Title Description
8339 Ceased/non-payment of the annual fee